Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GHSI Guardion Health Sciences	$3.22 -2.1%	$3.24	$3.04 ▼ $18.00	$4.35M	0.73	105,261 shs	4,700 shs
IMNN Imunon	$6.49 +2.9%	$10.61	$4.83 ▼ $41.22	$15.84M	2.16	415,803 shs	70,372 shs
LSB LakeShore Biopharma	$0.84 +2.0%	$0.96	$0.59 ▼ $8.60	$17.36M	0.56	130,562 shs	18,167 shs
NRSN NeuroSense Therapeutics	$1.18 +1.5%	$1.86	$0.67 ▼ $2.60	$16.09M	1.64	242,161 shs	593,346 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GHSI Guardion Health Sciences	0.00%	0.00%	0.00%	0.00%	-64.98%
IMNN Imunon	-2.62%	-7.75%	-23.79%	+5.38%	-65.23%
LSB LakeShore Biopharma	0.00%	+1.23%	-21.16%	-25.45%	-82.37%
NRSN NeuroSense Therapeutics	-7.20%	+3.57%	-43.14%	-22.67%	+51.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GHSI Guardion Health Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMNN Imunon	1.3834 of 5 stars	3.4	2.0	0.0	0.0	0.5	0.0	0.6
LSB LakeShore Biopharma	1.1371 of 5 stars	0.0	5.0	0.0	0.0	1.8	0.8	0.6
NRSN NeuroSense Therapeutics	2.2806 of 5 stars	3.5	3.0	0.0	0.0	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GHSI Guardion Health Sciences	0.00	N/A	N/A	N/A
IMNN Imunon	2.75	Moderate Buy	$232.50	3,482.43% Upside
LSB LakeShore Biopharma	0.00	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	3.00	Buy	$14.00	1,089.46% Upside

Current Analyst Ratings Breakdown

Latest GHSI, IMNN, LSB, and NRSN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/15/2025	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
7/10/2025	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GHSI Guardion Health Sciences	$12.25M	0.35	$0.14 per share	23.15	$6.39 per share	0.50
IMNN Imunon	$500K	31.67	N/A	N/A	$1.09 per share	5.95
LSB LakeShore Biopharma	$614.96M	0.03	N/A	N/A	$3.35 per share	0.25
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	($0.04) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GHSI Guardion Health Sciences	$160K	$4.87	0.66	∞	N/A	22.79%	-73.69%	-48.17%	N/A
IMNN Imunon	-$18.62M	-$12.95	N/A	N/A	N/A	N/A	-405.07%	-158.41%	11/6/2025 (Estimated)
LSB LakeShore Biopharma	-$13.93M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/21/2025 (Estimated)
NRSN NeuroSense Therapeutics	-$10.21M	-$0.54	N/A	∞	N/A	N/A	N/A	-445.40%	9/29/2025 (Estimated)

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GHSI Guardion Health Sciences	$5.00	155.28%	N/A	102.67%	N/A
IMNN Imunon	N/A	N/A	N/A	N/A	N/A
LSB LakeShore Biopharma	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest GHSI, IMNN, LSB, and NRSN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2025	IMNN Imunon	quarterly	$0.15	8.57%	8/7/2025	8/7/2025	8/21/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GHSI Guardion Health Sciences	N/A	16.68	16.59
IMNN Imunon	N/A	1.30	1.30
LSB LakeShore Biopharma	0.05	1.02	0.75
NRSN NeuroSense Therapeutics	N/A	0.71	2.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GHSI Guardion Health Sciences	20.21%
IMNN Imunon	4.47%
LSB LakeShore Biopharma	52.64%
NRSN NeuroSense Therapeutics	1.04%

Insider Ownership

Company	Insider Ownership
GHSI Guardion Health Sciences	1.32%
IMNN Imunon	5.96%
LSB LakeShore Biopharma	N/A
NRSN NeuroSense Therapeutics	27.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GHSI Guardion Health Sciences	10	1.35 million	1.33 million	Not Optionable
IMNN Imunon	30	2.44 million	2.30 million	Not Optionable
LSB LakeShore Biopharma	773	20.77 million	N/A	N/A
NRSN NeuroSense Therapeutics	10	13.67 million	9.92 million	Not Optionable

GHSI, IMNN, LSB, and NRSN Headlines

Recent News About These Companies

NeuroSense reports 20% of people with ALS from Phase 2a study remain on PrimeC

3 hours ago | msn.com

NeuroSense Reports Long-Term Safety of PrimeC in ALS Study

August 20 at 10:31 AM | tipranks.com

D. Boral Capital Reaffirms "Buy" Rating for NeuroSense Therapeutics (NASDAQ:NRSN)

August 17 at 3:31 AM | americanbankingnews.com

NeuroSense Provides Business Update and Progress for the First Half of 2025

August 1, 2025 | prnewswire.com

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

July 22, 2025 | prnewswire.com

NeuroSense Therapeutics Releases Q2 2025 Corporate Update

July 10, 2025 | tipranks.com

Neurosense Therapeutics Ltd News (NRSN) - Investing.com

July 2, 2025 | investing.com

NeuroSense Completes Key Meeting with Health Canada for ALS Drug Approval

June 26, 2025 | tipranks.com

Top Nasdaq Companies by Market Cap Ranked by Kalkine

June 7, 2025 | kalkinemedia.comK

Neurosense, awaiting Canada approval, scales PrimeC production

May 15, 2025 | alsnewstoday.comA

D. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy Recommendation

May 14, 2025 | msn.com

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

May 12, 2025 | benzinga.com

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

May 7, 2025 | prnewswire.com

NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership

April 24, 2025 | tipranks.com

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

April 24, 2025 | prnewswire.com

NeuroSense Therapeutics Presents Promising Phase 2b Data on PrimeC for ALS at AAN Meeting

April 10, 2025 | sohu.comS

NeuroSense Therapeutics Reports Year-End 2024 Financial Results and Provides Business Updates

April 10, 2025 | sohu.comS

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

April 9, 2025 | prnewswire.com

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

April 7, 2025 | prnewswire.com

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

April 4, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHSI, IMNN, LSB, and NRSN Company Descriptions

Guardion Health Sciences NASDAQ:GHSI

Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.

Imunon NASDAQ:IMNN

$6.49 +0.18 (+2.85%)

Closing price 04:00 PM Eastern

Extended Trading

$6.32 -0.17 (-2.54%)

As of 05:15 PM Eastern

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

LakeShore Biopharma NASDAQ:LSB

$0.84 +0.02 (+1.95%)

Closing price 03:57 PM Eastern

Extended Trading

$0.82 -0.02 (-2.03%)

As of 04:48 PM Eastern

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

NeuroSense Therapeutics NASDAQ:NRSN

$1.18 +0.02 (+1.47%)

Closing price 03:59 PM Eastern

Extended Trading

$1.17 -0.01 (-0.93%)

As of 05:27 PM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time